Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 11, 2014, Pages 1223-1225

  Bell, Carlos ^a   Chakravarty, Aloka ^a   Gruber, Susan ^a   Heckbert, Susan R ^b,c   Levenson, Mark ^a   Martin, David ^d   Nelson, Jennifer C ^e   Pinheiro, Simone ^a   Psaty, Bruce M ^b,c   Reich, Christian G ^f   Schneeweiss, Sebastian ^g   Shoaibi, Azadeh ^a   Toh, Sengwee ^h   Walker, Alexander M ⁱ  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f ASTRAZENECA   (United Kingdom)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h HARVARD PILGRIM HEALTH CARE INSTITUTE   (United States)

ⁱ WHISCON   (United States)

Author keywords

Electronic medical records; Insurance claims; Pharmacoepidemiology; Safety surveillance

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; CHEMICALLY INDUCED; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; HUMAN; METHODOLOGY; PHARMACOEPIDEMIOLOGY; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ELECTRONIC HEALTH RECORDS; HUMANS; PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN;

EID: 84920279917     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3712     Document Type: Note

References (5)

1. Platt R, Carnahan RM, Brown JS, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 1-8.
2. Ryan PB, Madigan D, Stang PE, et al. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. Stat Med 2012; 31(30): 4401-4415.
3. Inomata N. Recent advances in drug-induced angioedema. Allergol Int 2012; 61(4): 545-557.
4. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012; 172(20): 1582-1589. Erratum in: Arch Intern Med 2013; 173(1): 14.
5. Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol 2013; 178(4): 645-651.